Successful disease control with alemtuzumab in MOG-IgG-associated demyelinating disease with MS-phenotype

Mult Scler Relat Disord. 2020 Jul:42:102108. doi: 10.1016/j.msard.2020.102108. Epub 2020 Apr 15.

Abstract

Immunoglobulin G (IgG) antibodies against myelin oligodendrocyte glycoprotein in serum denote an emerging autoimmune disorder of the central nervous system. Treatment trials have not been performed so far and anecdotal reports suggest that immunotherapies approved for multiple sclerosis (MS) may not be effective. We report favorable disease control with alemtuzumab, a CD52 depleting antibody approved for active MS, in a 34-year-old woman with the rarer condition of MOG-IgG disease with MS-phenotype. MOG-IgG in serum persisted over the entire observation period of almost five years. This case emphasizes that treatment responses may be distinct for different phenotypes of MOG-IgG associated disease.

Keywords: Alemtuzumab; Demyelination; Disease control; Immunotherapy; Multiple sclerosis; Myelin oligodendrocyte glycoprotein.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Alemtuzumab / administration & dosage*
  • Demyelinating Autoimmune Diseases, CNS / diagnosis
  • Demyelinating Autoimmune Diseases, CNS / drug therapy*
  • Demyelinating Autoimmune Diseases, CNS / immunology*
  • Female
  • Humans
  • Immunologic Factors / administration & dosage*
  • Multiple Sclerosis / diagnosis
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / immunology
  • Myelin-Oligodendrocyte Glycoprotein / immunology*
  • Phenotype

Substances

  • Immunologic Factors
  • MOG protein, human
  • Myelin-Oligodendrocyte Glycoprotein
  • Alemtuzumab